Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS Associated…
Citius Pharmaceuticals, Inc. signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of…
Read More...
Read More...
